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factors contributing to development of
hypoxemia in moderate to severe COPD:
a cohort study
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Richard Casaburi8, Edwin J. R. van Beek9, Eric A. Hoffman10, Frank C. Sciurba11, James D. Crapo7,
Edwin K. Silverman5, Craig P. Hersh5 and the COPDGene InvestigatorsAbstract
Background: Hypoxemia is a major complication of COPD and is a strong predictor of mortality. We previously
identified independent risk factors for the presence of resting hypoxemia in the COPDGene cohort. However, little
is known about characteristics that predict onset of resting hypoxemia in patients who are normoxic at baseline.
We hypothesized that a combination of clinical, physiologic, and radiographic characteristics would predict
development of resting hypoxemia after 5-years of follow-up in participants with moderate to severe COPD
Methods: We analyzed 678 participants with moderate-to-severe COPD recruited into the COPDGene cohort who
completed baseline and 5-year follow-up visits and who were normoxic by pulse oximetry at baseline.
Development of resting hypoxemia was defined as an oxygen saturation ≤88% on ambient air at rest during
follow-up. Demographic and clinical characteristics, lung function, and radiographic indices were analyzed with
logistic regression models to identify predictors of the development of hypoxemia.
Results: Forty-six participants (7%) developed resting hypoxemia at follow-up. Enrollment at Denver (OR 8.30,
95%CI 3.05–22.6), lower baseline oxygen saturation (OR 0.70, 95%CI 0.58–0.85), self-reported heart failure (OR 6.92,
95%CI 1.56–30.6), pulmonary artery (PA) enlargement on computed tomography (OR 2.81, 95%CI 1.17–6.74), and
prior severe COPD exacerbation (OR 3.31, 95%CI 1.38–7.90) were independently associated with development of
resting hypoxemia. Participants who developed hypoxemia had greater decline in 6-min walk distance and greater
5-year decline in quality of life compared to those who remained normoxic at follow-up.
Conclusions: Development of clinically significant hypoxemia over a 5-year span is associated with comorbid heart
failure, PA enlargement and severe COPD exacerbation. Further studies are needed to determine if treatments
targeting these factors can prevent new onset hypoxemia.
Trial registration: COPDGene is registered at ClinicalTrials.gov: NCT00608764 (Registration Date: January 28, 2008)* Correspondence: jmwells@uabmc.edu
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Hypoxemia is a major complication of chronic obstruct-
ive pulmonary disease (COPD) and is associated with in-
creased mortality [1] and impaired exercise tolerance [2].
Hypoxemia contributes to other COPD-related complica-
tions including pulmonary vascular disease [3], skeletal
muscle dysfunction [4], and polycythemia [5]. Resting hyp-
oxemia has major implications related to morbidity, ther-
apy, and prognosis, unlike exercise induced desaturation
and nocturnal desaturation in COPD which have less well-
defined prognostic significance [6–9]. The Centers for
Medicare and Medicaid Services (CMS) defines the clinical
threshold for hypoxemia in stable COPD as arterial oxy-
genation (PaO2) ≤55 mmHg or pulse oximetry (SpO2)
≤88% [10–12]. Treatment of resting hypoxemia with sup-
plemental oxygen therapy is one of the few therapies for
COPD that improves quality of life, exercise tolerance, and
mortality [13–15]; thus, it is important to identify risk
factors for its development.
Previously, in cross sectional analyses, we demonstrated
that female sex, increased body mass index (BMI), lower
forced expiratory volume in 1-s (FEV1), and high altitude
(Denver, altitude 5280 ft) were independently associated
with resting oxygen saturation of ≤88% on ambient air
[16]. However, there is a paucity of information regarding
the development and impact of new onset hypoxemia
in COPD. Therefore, we hypothesized that a combin-
ation of clinical, physiologic, and radiographic characteris-
tics would predict development of resting hypoxemia after
5-years of follow-up in participants with moderate to se-
vere COPD. Further, we hypothesized that incident hypox-
emia would be associated with negative impacts on quality
of life, exercise performance, and lung function.
Methods
Subject selection
COPDGene is a prospective observational study con-
ducted at 21 clinical centers across the U.S., includingFig. 1 Patient Flow Diagram. Abbreviations: PRISm = Preserved Ratio, ImpaiNational Jewish Hospital in Denver [17]. In Phase 1,
COPDGene recruited 10,192 non-Hispanic white and
African-American current and former smokers (10 or
more pack-years) 45 years old or older with and without
COPD [17]. Participants are now returning for a Phase 2
visit approximately 5-years after their original visit. All
study participants were at baseline health status, defined
as no AECOPD within the previous 4 weeks, no surgery,
acute myocardial infarction, or hospitalization for a car-
diac problem within the previous 3 months, to standardize
conditions between Phase 1 and Phase 2 visits. Our
analysis used an interim dataset of the first 2000 Phase 2
participants. We included participants with moderate to
very severe COPD defined by Global Initiative for Chronic
Obstructive Lung Disease (GOLD) [18] spirometry grade
2-4 COPD at Phase 1, who did not have resting hypoxemia
at baseline. COPDGene was approved by the Institutional
Review Boards at participating institutions (Additional
file 1: Table S1, online supplement).Oxygen saturation measurement
Oxygen saturation was measured by pulse oximetry on
ambient air at both visits [17]. Pulse oximetry was ob-
tained with the subject in the seated position and the
value was recorded after the subject remained at rest in
the seated position for at least 5 min. The pulse oxim-
eter was placed on a finger without nail polish. The
median value obtained while observing the monitor
over a 1-min observation period was recorded. Pulse oxi-
meters were calibrated on a regular basis on a schedule
determined by the manufacturer’s recommendation and
the local clinical center bioengineering department. Study
coordinators were adequately trained in measurement in
pulse oximetry. If participants used supplemental oxygen,
oxygen was discontinued for 5 min prior to measurement
of pulse oximetry. If the oxygen saturation fell below 82%,
supplemental oxygen was restarted and 82% was recordedred Spirometry
Table 1 Baseline characteristics from Phase 1
Variable n = 678
Age, years 63 ± 8
Non-Hispanic white race 525 (77%)
Male sex 375 (55%)
Enrollment at Denver clinical site 132 (19%)
BMI, kg/m2 28.2 ± 5.8
Baseline heart rate, beats/min 76 ± 12
Baseline oxygen saturation, % 95.5 ± 2.4
Current Smokers 248 (37%)
Pack Year History 52 ± 26
Coronary Artery Disease 102 (15%)
Congestive Heart Failure 20 (3%)
Hypertension 315 (47%)
Hyperlipidemia 277 (41%)
Asthma 178 (26%)
Sleep apnea 137 (20%)
Thromboembolic disease 26 (4%)
Peripheral vascular disease 23 (3%)
Cerebrovascular disease 36 (5%)
Gastroesophageal reflux disease 215 (32%)
FEV1, percent predicted 54 ± 16
FEV1/FVC 0.51 ± 0.12
GOLD 2 405 (59.7%)
GOLD 3 215 (31.7%)
GOLD 4 58 (8.6%)
Percent emphysema, -950 HU 12.7 ± 11.7
Percent gas trapping 38 ± 19
PA/A ratio 0.89 ± 0.13
PA/A ratio >1 127 (19%)
Severe AECOPD 1-year prior 101 (15%)
MMRC 1.8 ± 1.4
SGRQ, total 35 ± 21
6MWD, ft 1277 ± 361
Values represent mean ± SD or n (%)
Definitions: FEV1 forced expiratory volume in 1-s, FVC forced vital capacity,
GOLD Global initiative for obstructive lung disease, PA pulmonary artery, A
aorta, AECOPD acute exacerbation of COPD, MMRC modified medical research
council, SGRQ St. George’s Respiratory Questionnaire, 6MWD 6-min
walk distance
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saturation ≤88% on ambient air [13, 14].
Study procedures
Both visits included spirometry before and after 2 puffs
of albuterol [19], 6 min walk testing (6MWT) [20], and
the St. George’s Respiratory Questionnaire (SGRQ) [21], a
measurement of quality of life (higher scores indicate
worse quality of life) and the modified medical research
council (MMRC) [22] dyspnea score. Comorbidities were
defined by subject self-report. Coronary artery disease was
defined as a positive response to history of coronary artery
disease, angina, myocardial infarction, percutaneous
coronary intervention, or coronary artery bypass graft
surgery.
Imaging
Participants underwent inspiratory and expiratory com-
puted tomography (CT) scans of the chest at the baseline
visit [17]. Emphysema was quantified by the percent of
low attenuation areas (%LAA) < -950 HU on full inspir-
ation [23] and gas trapping was quantified by %LAA
< -856 HU at relaxed expiration [24] using Slicer software
(www.slicer.org). The pulmonary artery (PA) and as-
cending aorta (A) diameters were measured as previously
reported; a PA/A ratio >1 indicated PA enlargement
[25, 26].
Statistical analysis
Hypoxemia was defined by a resting O2 saturation ≤ 88%
measured at the Phase 2 visit. Univariable logistic re-
gression was used to define associations between Phase 1
variables and the development of hypoxemia at Phase 2.
Variables associated at alpha < 0.10 on univariable analysis
were entered into a multivariable backward logistic regres-
sion model to include all potential factors associated with
hypoxemia at phase 2. Given the large percent of indi-
viduals recruited from the Denver site and the expected
impact of living at altitude, we performed a sensitivity
analysis using the multivariable logistic regression model
on the subgroup of participants not recruited in Denver.
T-tests were used to analyze differences in outcome
measures (change in SGRQ, MMRC, 6MWT, and FEV1)
between those who did and did not develop hypoxemia.
Significance was defined as a P < 0.05. Analysis used SPSS
for Windows Version 23 (IBM, USA).
Results
Subject characteristics
Of the 2000 participants who completed Phase 2 visits,
n = 678 met inclusion criteria (Fig. 1). As seen in Table 1,
participants were 63 ± 8 years old at Phase 1, 77% were
non-Hispanic white, and 55% were male with a predicted
FEV1 of 54 ± 16%. A total of 132 (19%) individuals wereenrolled in Denver. At baseline, heart rate was 76 ± 12
beats/min and oxygen saturation was 95.5 ± 2.4%. Self-
reported comorbid conditions included coronary artery
disease (15%), congestive heart failure (3%), diabetes (11%),
sleep apnea (20%), thromboembolic disease (4%), periph-
eral vascular disease (3%), and cerebrovascular disease
(5%). On CT imaging, mean percent emphysema was 12.7
± 11.7%, gas trapping was 38 ± 19%, and 19% of partici-
pants had a PA/A ratio >1.
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The median follow-up time was 64 (range 51–78) months.
As exhibited in Fig. 2, the change in resting oxygen
saturation was normally distributed with a mean decrease
of 1% over the 5-year period. Between Phase 1 and Phase
2 visits, 46 patients (7%) of patients developed hypoxemia
at Phase 2.
Predictors of the development of hypoxemia at rest
Development of a resting oxygen saturation ≤88% at Phase
2 was predicted by several baseline variables using univari-
able logistic regression (Table 2). In the multivariable
model, enrollment at Denver, lower oxygen saturation at
baseline, self-reported CHF, PA/A ratio >1, and having a se-
vere AECOPD within 12-months prior to study entry were
independently associated with the development of hypox-
emia (Table 3). We observed a negative correlation between
baseline CT percent emphysema and follow-up oxygen sat-
uration (R = -0.23, P < 0.001). COPD cases who developed
hypoxemia had higher baseline percent emphysema than
those who did not develop hypoxemia (15.8 ± 10% versus
12.5 ± 10%, P = 0.015), though emphysema did not inde-
pendently contribute to the regression model. Percent
gas trapping on CT was not significantly elevated in
cases that developed hypoxemia compared to those
who did not (43.1 ± 13.7% versus 37.6 ± 19%, P = 0.057).
We performed a sensitivity analysis by excluding the
132 participants (n = 32 who developed hypoxemia)Fig. 2 Distribution of change in oxygen saturation over a 5-year period amenrolled in Denver. As demonstrated in Table 4, lower
baseline oxygen saturation, CHF, and a previous severe
exacerbation remained independently associated with
the development of hypoxemia, mirroring findings from
the entire cohort.
Associations between incident hypoxemia, quality of life,
and 6-min walk distance
The development of hypoxemia adversely impacted
quality of life, exercise tolerance, and dyspnea (Fig. 3).
The change in total SGRQ (8.0 ± 2.1 versus 1.4 ± 0.6
points, P = 0.003), activity subscore (9.1 ± 2.5 versus 3.8
± 0.8, P = 0.05), and impact subscore (8.5 ± 2.4 versus
0.6 ± 0.6, P = 0.002) were significantly higher in COPD
cases who did vs. those who did not develop resting
hypoxemia. The difference in change in SGRQ symp-
tom score was not significant (4.2 ± 3.1 versus -0.3 ± 0.9,
P = 0.18). COPD cases who developed hypoxemia had a
trend towards increased dyspnea (change in MMRC 0.52
± 0.17 versus 0.17 ± 0.05, P = 0.053). We observed a 3-fold
greater decline in 6MWD (-440 ± 62 versus -141 ± 14 ft.
[-134 ± 19 versus -43 ± 4 m], P < 0.001) in participants
who developed hypoxemia.
Discussion
We showed that there is substantial variability in the
change in oxygen saturation over a 5-year period in
non-hypoxemic participants with moderate to severeong COPD cases without hypoxemia at baseline (n = 678)
Table 2 Variables associated with the development hypoxemia
at rest among COPD cases
Variable OR 95% CI P-value
Age, per 1 year increase 1.05 1.01–1.09 0.021
African American race 3.24 1.14–9.18 0.027
Male sex 1.41 0.76–2.62 0.28
Enrollment at Denver clinical site 12.2 6.26–23.6 <0.001
BMI, kg/m2 0.98 0.93–1.04 0.47
Baseline heart rate, beat/min 1.02 0.99–1.04 0.20
Baseline oxygen saturation, % 0.62 0.54–0.70 <0.001
Current Smokers 0.67 0.34–1.29 0.23
Pack Year History 1.01 1.00–1.02 0.05
Coronary artery disease 1.41 0.66–3.02 0.38
Congestive heart failure 5.02 1.74–14.5 0.003
Hypertension 0.59 0.32–1.11 0.10
Hyperlipidemia 1.23 0.68–2.25 0.49
Asthma 1.28 0.97–1.70 0.08
Sleep apnea 1.28 0.96–1.70 0.09
Thromboembolic disease 1.15 0.26–5.02 0.85
Peripheral Vascular Disease 1.32 0.30–5.81 0.71
Cerebrovascular Disease 1.26 0.37–4.29 0.71
Gastroesophageal reflux 1.72 0.94–3.16 0.08
FEV1, percent predicted 0.98 0.96–0.99 0.02
Percent emphysema 1.02 0.99–1.05 0.09
Percent gas trapping 1.02 0.99–1.03 0.09
PA/A ratio >1 2.02 1.04–3.92 0.038
Severe AECOPD within 12 months 2.98 1.56–5.67 0.001
Data represents univariable associations as determined by logistic
regression analysis
Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index, FEV1
forced expiratory volume in 1-s, FVC forced vital capacity, PA/A pulmonary
artery to aorta ratio, AECOPD acute exacerbation of chronic obstructive
pulmonary disease
Table 3 Independent predictors of incident resting hypoxemia
in individuals with COPD
Variable OR 95% CI P-value
Enrollment at Denver clinical site 8.30 3.05–22.6 <0.001
Baseline oxygen saturation, % 0.70 0.58–0.85 <0.001
Congestive heart failure 6.92 1.56–30.6 0.01
PA/A ratio >1 2.81 1.17–6.74 0.02
Severe AECOPD within 12-months 3.31 1.38–7.90 0.007
Variables included in the backwards multivariate logistic regression model:
age, race, sex, Denver, baseline oxygen saturation, pack-year history of tobacco
use, congestive heart failure, hypertension, asthma, sleep apnea, gastroesophageal
reflux disease, FEV1 percent predicted, percent emphysema, percent gas trapping,
PA/A > 1, severe AECOPD within 12-months of visit (R2 = 0.39, P < 0.001).
Abbreviations: OR = odds ratio, CI = confidence interval, PA/A = pulmonary
artery to aorta ratio, AECOPD = acute exacerbation of chronic obstructive
pulmonary disease
Table 4 Multivariable logistic associations with the development
of hypoxemia in subjects recruited from non-Denver sites
Variable OR 95% CI P-value
Baseline oxygen saturation, % 0.77 0.60–0.99 0.04
Congestive heart failure 7.22 1.66–31.3 0.008
Severe AECOPD within 12 months 4.26 1.33–13.6 0.015
This analysis is of the subgroup (n = 546) not recruited at Denver. Variables
included in the backwards stepwise logistic regression model: age, race, sex,
baseline oxygen saturation, congestive heart failure, FEV1 percent predicted,
PA/A > 1, and severe AECOPD within 12-months of visit
Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index, FEV1
forced expiratory volume in 1-s, FVC forced vital capacity, PA/A pulmonary
artery to aorta ratio, AECOPD acute exacerbation of chronic obstructive
pulmonary disease
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tion, and we identified multiple risk factors that are as-
sociated with incident hypoxemia at rest. Modifiable
risk factors include living at high altitude and COPD
exacerbations, and non-modifiable risk factors include
baseline oxygen saturation, comorbid CHF, and pulmon-
ary arterial enlargement on CT. Incident hypoxemia was
associated with accelerated FEV1 decline, poorer quality of
life, and shorter 6MWD.
Our results were consistent with prior analyses examin-
ing the longitudinal change in oxygen saturation and add
to our understanding by adding imaging based metrics to
clinical factors known to be associated with hypoxemia. In
a population-based study of 2822 participants in Norway
including 23.1% with COPD, Vold and colleagues reported
that there was not an overall change in mean oxygen
saturation over 6.3 years [27]. Only 25 participants (0.9%)
in their study developed an oxygen saturation ≤92%,
whereas 14% in our study developed an oxygen saturation
≤88%. Possible explanations for the differences between
studies are the inclusion of participants enrolled at high
altitude in COPDGene as well as genetic and racial varia-
tions. Despite these differences in study outcomes, Vold et
al identified male sex, FEV1 ≤ 50% predicted, ≥10 pack-
years smoking history, BMI ≥30 kg/m2, and C-reactive
protein ≥5 mg/L as independent predictors of an oxygen
saturation decline of ≥2%. In another 3-year study of 419
participants with GOLD 2 to 4 stage COPD, Saure and
colleagues found no significant change in PaO2 over time,
but 15% of the normoxic participants developed at least
one episode of hypoxemia [28]. They did not identify any
variables predictive of change in PaO2.
While the overall change in oxygen saturation was
similar between our findings and prior publications, we
found that hypoxemia develops in an appreciable portion
(7%) of participants with moderate-to-severe COPD in
our cohort. The factors associated with resting hypoxemia
are related to lower resting oxygen saturation at baseline,
episodic hospitalizations for AECOPD, chronic effects of
high altitude, and cardiovascular comorbidities. The major
Fig. 3 Development of hypoxemia is associated with worsened QOL and reduced exercise tolerance. Compared to normoxic participants at
Phase 2, participants who developed hypoxemia had a greater rate of change in a SGRQ total score, b SGRQ activity score, c SGRQ impact score,
but no difference of change in d SGRQ symptom score or breathlessness measured by e MMRC. Likewise, these participants have a greater
decrease in f 6MWD change compared to participants who remained normoxic. Error bars represent standard error. SGRQ = St George’s
Respiratory Questionnaire, 6MWD = 6-min walk distance. MMRC =modified medical research council score. *P < 0.05, **P < 0.01, ***P < 0.001
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tion/perfusion mismatch due to airflow limitation [29]
and emphysematous destruction of the capillary bed [30].
Gas exchange abnormalities present in stable COPD
acutely worsen during AECOPD due to effects of inflam-
mation, exaggerated V/Q mismatch, and increased oxygen
consumption [31]. Our observations that low FEV1 and
previous severe AECOPD contribute to oxygen saturation
decline and incident hypoxemia are expected sequelae of
these pathophysiologic processes. This leads one to posit
the possibility that earlier and more aggressive treat-
ment of underlying lung disease or preventing/minimizing
inflammation following AECOPD may forestall the pro-
gression of hypoxemia.Several factors associated with incident hypoxemia
and oxygen saturation decline are related to cardiovas-
cular and pulmonary vascular disease. We found that
high altitude had the strongest association. It is well
established that chronic residence at high altitude is
associated with an increased mortality and higher
incidence of cor pulmonale in COPD [32, 33]. While
short-term studies have been performed evaluating the
contribution of altitude on hypoxemia in COPD [34],
our findings are the first to report long term changes in
oxygen saturation in COPD patients living at high
altitude. Given that living in Denver was such a strong
independent predictor of the development of hypox-
emia in COPD, this might suggest that patients with
Wells et al. BMC Pulmonary Medicine  (2016) 16:169 Page 7 of 9COPD should be advised to move to lower altitudes if
these findings are recapitulated in additional studies.
Pulmonary arterial enlargement was the only chest
CT metric that was associated with development of
hypoxemia. We have previously shown that the PA/A
ratio correlates with invasive hemodynamic measure-
ments [35], early right ventricular dysfunction [25], and
is predictive of severe AECOPD [26]. Pulmonary arter-
ial enlargement likely represents a common measurable
endpoint for the consequences of prolonged exposure
to high altitude, ventricular failure, or idiopathic pulmon-
ary hypertension. Although CT emphysema was higher
in participants who developed hypoxemia and corre-
lates with follow-up oxygen saturation, it did not inde-
pendently contribute to oxygen saturation decline.
These findings are in agreement with Dournes and col-
leagues’ recent work [36] suggesting that CT metrics of
vascular and airway remodeling, but not emphysema,
predict oxygen saturation and pulmonary hypertension
in COPD. It is possible that other CT metrics not mea-
sured in COPDGene, including lung surface area [37]
or small vessel volumes [25, 38] could also be related to
the development of hypoxemia.
We also found a strong association between self-
reported CHF and the development of hypoxemia. Patients
with CHF, like those with COPD, depend on hypoxic vaso-
constriction to maintain normal gas exchange [39]. While
CHF is not commonly associated with hypoxemia in the
absence of other contributing factors, heart failure in the
context of cor pulmonale is related to gas exchange abnor-
malities and hypoxemia in COPD [40]. Consequences of
concomitant chronic left ventricular impairment and
COPD could be contributory to the development of
hypoxemia [41] including residual gas exchange abnormal-
ities stemming from episodic hypoxemia due to heart
failure exacerbations [42, 43], intravascular shunting [44],
or thromboembolic disease [45].
Incident resting hypoxemia had important implications.
Poor quality of life, measured by the SGRQ, is associated
with dyspnea, depression, and anxiety, and carries an
increased risk for hospitalization and death [46, 47].
Hypoxemia also contributes to worsened SGRQ scores
[48], though supplemental oxygen does not improve
SGRQ scores in hypoxemic [49] and normoxic patients
[50], highlighting the importance of addressing modifiable
risk factors to prevent the decline in oxygen saturation.
Small studies have shown that long-term supplemental
oxygen therapy prevents exercise induced desaturation,
improves walk distance, and improves dyspnea [8, 51]
while others show limited benefit of therapy [52–54].
Clinical equipoise regarding treatment of mild-to-
moderate hypoxemia in COPD may be addressed by
the results of the upcoming long-term oxygen treat-
ment trial (LOTT) [55].Our study had several limitations. First, due to the
observational nature, we were unable to assign causality
between the risk factors identified and development of
hypoxemia. Comorbidities were self-reported and may
reflect over- or under-representation of comorbid condi-
tions in this COPD cohort. Our study was also limited
by the interim data analysis of the first 2000 Phase 2 par-
ticipants; these results may not be reflective of the entire
cohort. Additionally, we used pulse oximetry to assess
oxygen saturation as arterial blood gases were not in-
cluded in the COPDGene study protocol. While arterial
blood gas analysis remains the gold standard for measur-
ing oxygen concentration in COPD, pulse oximetry is
widely used as a surrogate for evaluating hypoxemia in
clinical practice [56, 57], increasing the generalizability
of our findings. Finally, oxygen saturations were only
measured on two occasions, limiting further conclusions
about disease trajectory and raising the question about
variability. When Saure and colleagues measured PaO2
at multiple intervals over a 3-year period, they found
highly conserved values [28], suggesting that our method
and findings are valid.
Conclusions
Hypoxemia remains a critical development in the natural
history of COPD. Our findings provide some insight into
the complexities of the development and progression of
hypoxemia in moderate to severe COPD and highlight
the important contribution that high altitude and cardio-
vascular disease have on its incidence and may represent
additional targets for future interventions.
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